CUMBERLAND PHARMACEUTICALS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
TN
Business Address
1600 WEST END AVENUE, NASHVILLE,, TN, 37203
Mailing Address
1600 WEST END AVENUE, NASHVILLE, TN, 37203
Phone
615-255-0068
Fiscal Year End
1231
EIN
621765329
Financial Overview
FY2025
$1.26M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
Annual Reports
10-K
March 9, 2026
- Announced 'breakthrough' clinical study results for Ifetroban in Duchenne muscular dystrophy (DMD), leading to discussions with the FDA.
- Initiated two new FDA-approved Phase II clinical studies for Ifetroban in Systemic Sclerosis (SSc) and Idiopathic Pulmonary Fibrosis (IPF).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.